Today: 19 November 2025
Subscribe
Browse Category

Biotech News 26 August 2025 - 6 October 2025

Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Stock Performance & Recent Price Action Spruce Biosciences’ stock has been on a wild ride in early October 2025. Heading into this period, SPRB was a little-known micro-cap biotech trading in the high single digits (post-reverse-split). At the close on Oct 3, 2025, shares stood at $8.82 (market cap ~$4.8M) stocktitan.net after a period of relatively low activity. That calm shattered on Oct 6, when news of an FDA breakthrough designation sent the stock skyrocketing. SPRB opened the day with a huge gap up and at one point surged by 250–300% intraday, hitting roughly $31–$32 per share benzinga.com stocktwits.com. Benzinga
6 October 2025
 ·  ·  ·  ·  · 
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (NASDAQ: CDTX) 2025 Investment Analysis – Will This Anti‑Flu Innovator Keep Soaring?

2025 Year‑to‑Date Stock Performance Cidara’s stock has been among the best performers in biotech. According to YTDReturn.com, a US$10,000 investment on 31 Dec 2024 would have grown to ~US$37,943 by 3 Oct 2025 because the share price increased from US$26.88 to US$101.99, a 279.43 % YTD return ytdreturn.com. Zacks similarly reported a 217.8 % YTD rally by late September nasdaq.com, reflecting further gains in October. The stock traded between US$10.14 and US$106.63 over the past year stockanalysis.com and surged 695.5 % year‑on‑year nasdaq.com. The rally was driven by positive trial data, accelerated regulatory milestones and speculative interest. Cidara’s Cloudbreak platform generated excitement because the CD388 candidate could
4 October 2025
 ·  ·  ·  ·  ·  · 
Regencell (RGC) Stock Skyrockets 64,000% – Miracle Biotech or Bubble?

Regencell (RGC) Stock Skyrockets 64,000% – Miracle Biotech or Bubble?

RGC’s 2025 Rollercoaster: From Penny Stock to $33B Phenomenon Regencell Bioscience’s journey in 2025 has been nothing short of astonishing. The company went from an obscure penny stock (literally trading under 10 cents) to a meteoric high of $83.60 within months stockanalysis.com. This 820-fold increase was “far stranger” than a typical biotech breakthrough – it happened without any major scientific news or product launch gurufocus.com. Instead, a perfect storm of speculative forces sent RGC into the stratosphere. The catalyst was announced in early June: a 38-for-1 stock split. Overnight, Regencell’s share count multiplied and the price per share dropped from
4 October 2025
 ·  ·  ·  ·  · 
Mesoblast Stock Jumps on Ryoncil Milestone – Analysts See 40% Upside

Mesoblast Stock Jumps on Ryoncil Milestone – Analysts See 40% Upside

Mesoblast’s stock has surged recently on the Ryoncil news. At the Oct 2 close it stood at $17.02 – up +4.6% on the day and roughly +8% from two weeks prior stockinvest.us marketbeat.com. This rally follows last week’s announcements: on Sept 26 the company announced its therapies are U.S.-origin and exempt from tariffs nasdaq.com, and on Oct 2 it disclosed that CMS has made the HCPCS J‐Code for Ryoncil (J3402) permanent starting Oct 1 stocktitan.net. CEO Silviu Itescu called the new J-code “a critical element for successful commercialization of rare disease products, ensuring more efficient billing and enabling timely access
3 October 2025
 ·  ·  ·  ·  ·  · 
Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Stock Performance and Trends Sarepta’s stock is recovering some ground after steep losses. As of Oct 2, 2025, SRPT closed at $19.57, up about 6.8%for the day investing.com. This followed a general uptrend in recent weeks: SRPT is up roughly 16% over the last month marketbeat.com (though still down >80% from early 2025 levels). Trading volume has been moderate (0.6 million on Oct 2 vs. ~5–9M in prior days) investing.com. Over five trading days it gained +14.6% marketbeat.com, reflecting renewed investor interest. By contrast, the stock had sunk to ~$10–12 in mid-2025 amid safety concerns. Year-to-date, SRPT’s performance is dismal: a –82% return in one year marketbeat.com,
2 October 2025
 ·  ·  ·  ·  ·  · 
Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Stock Price Performance (YTD & Recent) Crinetics stock has been volatile but trending upward in 2025, with the recent FDA catalyst propelling it sharply higher. On September 26, 2025, CRNX closed around $45–$46, up roughly +28% in a single day reuters.com. This spike followed the Palsonify approval news and likely a short squeeze, given the high short interest (~14 million shares short, ~15.5% of float) prior to the decision marketbeat.com marketbeat.com. The one-year trading range spans $24.10 – $62.53 marketbeat.com, meaning the stock is now nearly double its 52-week low and about 26% below its 2023 high. In other words,
26 September 2025
 ·  ·  ·  ·  ·  · 
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Stock and Company Update as of September 24, 2025 Stock Performance & Technical Analysis Cidara’s stock has been on a tear in 2025, delivering triple-digit percentage gains. Year-to-date, CDTX has risen about +173% as of late September investing.com, driven by upbeat trial results and investor enthusiasm for its flu program. The stock recently surged over 20% in one day after the Phase 3 acceleration news, reaching an intraday high of approximately $87.75 on Sept. 24 marketbeat.com marketbeat.com. This is effectively a new 52-week (and all-time) high, far above its 52-week low of ~$10 marketbeat.com. By comparison, Cidara’s market capitalization now stands around $2.0–2.3 billion at these prices
24 September 2025
 ·  ·  ·  ·  · 
Engineered Living Therapeutics: How “Bugs as Drugs” Are Transforming Medicine in 2025

Engineered Living Therapeutics: How “Bugs as Drugs” Are Transforming Medicine in 2025

Introduction: Living Cells as Medicine Imagine treating disease by swallowing a pill full of programmed bacteria that take up residence in your gut and produce medicines from within. This sci-fi concept is rapidly becoming reality. Engineered Living Therapeutics (ELTs) refer to any modified live cells – from microbes to human immune cells – that are used as treatment. Instead of manufacturing a drug in a factory, ELTs turn a living cell into the drug factory inside the patient. In 2025, this field has exploded into the spotlight: the World Economic Forum identified ELTs as one of the year’s top emerging
10 September 2025
 ·  ·  ·  · 
Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Key Facts Scientific Breakthroughs & New Research Leading our roundup are several significant scientific and medical breakthroughs. Researchers in New York unveiled a potential “universal” antiviral strategy, reporting compounds that neutralized seven different viruses across multiple families in lab tests gavi.org. By targeting sugar molecules (glycans) common to many enveloped viruses, the team identified four small molecules that blocked infections by pathogens ranging from coronaviruses to Nipah and Ebola gavi.org. “This is the kind of antiviral tool the world urgently needs. If a new virus emerges tomorrow, we currently have nothing to deploy. These compounds offer the potential to be
30 August 2025
 ·  ·  ·  ·  ·  ·  · 
Billion-Dollar Pharma Deals, Biotech Breakthroughs & Global Health Alerts – Biotech & Health News Roundup (Aug 25–26, 2025)

Billion-Dollar Pharma Deals, Biotech Breakthroughs & Global Health Alerts – Biotech & Health News Roundup (Aug 25–26, 2025)

Biotech & Pharma Industry Updates Regulatory & Drug Approvals Clinical Trials & Innovations Medical Research Highlights Health Policy & Government Public Health & Global Health Alerts Sources: This report draws on recent press releases and expert commentary from Reuters, AP, and industry outlets (with citations) to provide an accurate and timely summary of developments. Readers are encouraged to consult the linked sources reuters.com reuters.com and official health agency updates for more detailed information.
26 August 2025
 ·  ·  ·  ·  · 
AI Storm: $10B Cloud Deals, Biotech Breakthroughs & Backlash (Aug 25–26, 2025 AI News Roundup)

AI Storm: $10B Cloud Deals, Biotech Breakthroughs & Backlash (Aug 25–26, 2025 AI News Roundup)

Meta inked a six-year cloud deal worth over $10 billion with Google to power its AI push, as Meta raised its 2025 capital expenditure forecast to $66–72 billion and moved to offload $2 billion in data-center assets. Nvidia unveiled a GeForce NOW upgrade to run the Blackwell RTX 5080-class GPUs, enabling 5K at 120 fps and up to 360 fps at 1080p with DLSS 4, announced at Gamescom. OpenAI announced its first international office in New Delhi later in 2025 and launched the cheapest-ever ChatGPT plan in India at about $4.60 per month. The U.S. General Services Administration sealed a
26 August 2025
 ·  ·  ·  ·  ·  ·  ·  · 
1 … 3 4 5 6 7
Go toTop